What Facts Should You Know About NeoGenomics (NEO)?

NeoGenomics logged a 1.6% change during today's morning session, and is now trading at a price of $13.74 per share. On average, analysts give it a target price of $21.18.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The small-cap company is based in the United States.

Make Sure to Consider the Following Before Buying NeoGenomics:

  • NeoGenomics has moved 14.0% over the last year.

  • NEO has a forward P/E ratio of -80.8 based on its EPS guidance of -0.17.

  • Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of -16.7%.

  • The company has a price to earnings growth (PEG) ratio of -34.67.

  • Its Price to Book (P/B) ratio is 1.83

NeoGenomics Has Irregular and Negative Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-12-31 -65,993 -30,891 -96,884 -6.62
2021-12-31 -26,723 -64,142 -90,865 -228.79
2020-12-31 1,460 -29,096 -27,636 -927.43
2019-12-31 23,369 -20,029 3,340 n/a

NeoGenomics has negative and highly variable free cash flows. They've averaged $-53.01 Million over the last 4 years, during which time they grew at a -16.3% compounded rate while displaying a coefficient of variability of 92.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.